Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Non-Current Assets (2022 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed Non-Current Assets for 4 consecutive years, with $22.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Non-Current Assets rose 11.1% to $22.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $96.9 million, a 66.53% increase, with the full-year FY2025 number at $22.7 million, up 11.1% from a year prior.
  • Non-Current Assets was $22.7 million for Q4 2025 at Day One Biopharmaceuticals, down from $23.8 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $25.7 million in Q1 2025 to a low of $611000.0 in Q1 2024.
  • A 4-year average of $13.2 million and a median of $18.5 million in 2024 define the central range for Non-Current Assets.
  • Peak YoY movement for Non-Current Assets: tumbled 34.85% in 2023, then surged 4107.04% in 2025.
  • Day One Biopharmaceuticals' Non-Current Assets stood at $1.2 million in 2022, then crashed by 34.85% to $774000.0 in 2023, then skyrocketed by 2543.15% to $20.5 million in 2024, then grew by 11.1% to $22.7 million in 2025.
  • Per Business Quant, the three most recent readings for DAWN's Non-Current Assets are $22.7 million (Q4 2025), $23.8 million (Q3 2025), and $24.6 million (Q2 2025).